Business Context and Reporting Period
This Form 8-K Current Report was filed by PMV Pharmaceuticals, Inc. on November 3, 2022. The filing addresses corporate governance changes, specifically the resignation of a director and the subsequent appointment of a new director to the Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on personnel changes within the Board of Directors.
Material Changes
- Resignation of Director: Thilo Schroeder, Ph.D., resigned as a member of the Board of Directors, the Audit Committee, and the Nominating and Corporate Governance Committee, effective November 3, 2022. The resignation was not related to any disagreement with the Company regarding operations, policies, or practices.
- Election of Director: Carol Gallagher, Pharm.D., was unanimously appointed as a Class I director to fill the vacancy created by Dr. Schroeder's resignation, effective November 3, 2022. Her term expires at the 2024 annual meeting of stockholders.
- Committee Appointments: Kirsten Flowers was appointed to the Audit Committee, and Dr. Gallagher was appointed to the Nominating and Corporate Governance Committee.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies. Dr. Gallagher's compensation will align with the Company's Outside Director Compensation Policy, and she has entered into a standard indemnification agreement with the Company. No family relationships or undisclosed material interests were reported.
Investor Verification Checklist
- Verify the composition of the Board of Directors and committee memberships following the November 3, 2022 changes.
- Review the press release dated November 4, 2022 (Exhibit 99.1) for additional context on the appointment.
- Confirm the terms of the Outside Director Compensation Policy referenced in the filing.